Formosa Pharmaceuticals, Inc. (6838.TWO)
Taipei Exchange - Taipei Exchange Delayed price. Currency in TWD
Add to watchlist
At close: 02:59PM CST
| Previous close | 53.50 |
| Open | 54.00 |
| Bid | 53.00 x N/A |
| Ask | 53.40 x N/A |
| Day's range | 52.90 - 54.00 |
| 52-week range | 49.00 - 66.90 |
| Volume | |
| Avg. volume | 450,249 |
| Market cap | 7.177B |
| Beta (5Y monthly) | 1.03 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.59 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireEyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
Approval based on nearly 9 out of 10 patients achieving complete absence of post-surgical pain and 6 out of 10 achieving total absence of inflammation within 15 days post-ocular surgery Eyenovia plans to launch in the U.S. as soon as this summer using its Mydcombi™ sales force providing pre-surgical pupil dilation and post-surgical care in an estimated $1.3 billion annual U.S. market NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company
© 2024 Yahoo. All rights reserved.